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Abstract
Objective: Narcolepsy (with and without cataplexy) and idiopathic hypersomnia, are disorders with common features but with different 
HLA-DQB1*0602 allele prevalence. The present study describes the prevalence of HLA-DQB1*0602 allele in narcoleptics with and 
without cataplexy and in patients with idiopathic hypersomnia. Method: Subjects comprised 68 patients who were diagnosed for 
narcolepsy or idiopathic hypersomnia and 23 healthy controls according to the International Classification of Sleep Disorders-2. Subjects 
comprised 43 patients with narcolepsy and cataplexy, 11 patients with narcolepsy but without cataplexy, 14 patients with idiopathic 
hypersomnia and 23 healthy controls. Genotyping of HLA-DQB1*0602 allele was performed for all subjects. Results: The prevalence 
of the HLA-DQB1*0602 allele was increased in idiopathic hypersomnia and in narcoleptic patients with and without cataplexy when 
compared to healthy subjects (p = 0.04; p = 0.03 and p < 0.0001, respectively). Conclusions: This finding is in accordance with those 
of previous studies. The gold standard exam of narcolepsy with cataplexy is Hypocretin-1 dosage, but in patients without cataplexy and 
idiopathic hypersomnia, there are no specific diagnostic lab findings. The presence of the HLA-DQB1* 0602 allele may  be important 
for the differential diagnosis  of situations that resemble those sleep disorders such as secondary changes in sleep structure due to 
drugs’ consumption.
Descriptors: HLA-DQB1*0602 allele; Narcolepsy; Hypersomnolence, idiopathic; Outpatients; Diagnosis/methods
Resumo
Objetivo: Narcolepsia (com e sem cataplexia) e hipersonolência idiopática são transtornos com características clínicas comuns, mas 
com prevalências do alelo HLA-DQB1*0602 diferentes. Este estudo descreve a prevalência do alelo HLA-DQB1*0602 em pacientes 
narcolépticos com e sem cataplexia e em pacientes com hipersonolência idiopática. Método: A amostra consistiu de 68 pacientes 
com diagnóstico de narcolepsia ou hipersonolência idiopática e 23 controles saudáveis segundo o International Classification of Sleep 
Disorders-2. A amostra foi composta de 43 pacientes com narcolepsia e cataplexia, 11 pacientes com narcolepsia e sem cataplexia, 
14 pacientes com hipersonolência idiopática e 23 controles saudáveis. A análise da presença do alelo HLA-DQ*0602 foi realizada 
em todos os sujeitos. Resultados: A prevalência do alelo HLA-DQB1*0602 foi maior nos grupos de pacientes com hipersonolência 
idiopática e em pacientes narcolépticos com e sem cataplexia quando comparada com a dos sujeitos saudáveis (p = 0,04; p = 0,03 
e p < 0,0001, respectivamente). Conclusões: Os resultados são compatíveis com o de estudos anteriores. O exame padrão-ouro 
para a confirmação da narcolepsia em pacientes com cataplexia é a dosagem de hipocretina, mas em pacientes sem cataplexia e 
hipersonolência idiopática não há testes laboratoriais específicos para o diagnóstico. A presença do alelo HLA-DQB1*0602 pode ser 
importante no diagnóstico diferencial de situações semelhantes a esses distúrbios do sono, como alterações secundárias na estrutura 
do sono causadas por consumo de drogas.
Descritores: Alelo HLA-DQB1*0602; Narcolepsia; Hipersonolência idiopática; Pacientes ambulatoriais; Diagnóstico/métodos
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Introduction
Narcolepsy is characterized by excessive daytime sleep (EDS) 
and cataplexy. Sleep paralysis and hypnagogic hallucinations can 
be added to this clinical picture1,2. Two or more sleep onset rapid 
eye movement periods (SOREM) using a Multiple Sleep Latency 
Test performed after nocturnal polysomnography can be helpful 
in diagnosing narcolepsy in the absence of a convincing history 
of partial or complete attacks of cataplexy2,3. Narcolepsy studies 
show a frequent association of the HLA-DQB1*0602 allele with 
the presence of cataplexy4.
The HLA-DQB1*0602 allele prevalence has been demonstrated 
in asymptomatic population: 25% of Caucasians, 12% in Japanese 
and 38% in African-Americans1. However, the prevalence of the HLA-
DQB1*0602 allele has been described in 95% of Caucasian patients 
with cataplexy and in 40-50% of patients without cataplexy.  This would 
strengthen the hypothesis of a genetic contribution for the disease. Other 
pathophysiological hypotheses derive from the environment, including 
infections and the immunological system response.
Idiopathic hypersomnia (IH) is a sleep disorder of the central 
nervous system characterized by prolonged nocturnal sleep and 
periods of daytime drowsiness. Affected individuals experience 
sleep drunkenness, automatic behavior, and memory disturbances. 
This condition differs from narcolepsy in that daytime sleep periods 
are longer, there is no association with cataplexy, and multiple 
sleep latency onset tests do not record SOREM2. The International 
Classification of Sleep Disorders-2 (ICSD-2)2 divided IH in patients 
with and without long sleep duration. Some authors failed to 
describe the increase of the HLA-DQB1*0602 allele in idiopathic 
hypersomnia5,6.
Patients with cataplexy have a greater prevalence of the HLA-
DQB1*0602 allele along with a marked diminution of Hypocretin-1 in 
the cerebral spinal fluid when compared with patients without cataplexy 
or IH7. There is a dearth of immunological studies in the literature which 
focus on patients with narcolepsy in which clinical and laboratory 
differences were assessed8. These differences, which also include the 
frequency of cataplexy, prevalence of the HLA-DQB1*0602 allele and 
lower levels of Hypocretin-1 in the cerebral spinal fluid, encouraged 
some investigators to posit a pathophysiological discrepancy in sleep 
disorders8. 
The investigation of the HLA-DQB1*0602 allele is not a routine 
procedure. The presence of the HLA DQB1*0602 allele could be 
important for the differential diagnosis of situations that resemble those 
sleep disorders such as drugs changing sleep structure and others.
Our study was to investigate the prevalence of the HLA-
DQB1*0602 allele in patients with narcolepsy with cataplexy, 
patients with narcolepsy without cataplexy, and patients with IH 
with a long sleep duration.  
 Method
The study was prospective and was undertaken between 
November 2003 and February 2008 at the Sleep Institute, 
Department of Psychobiology, Universidade Federal de São Paulo 
(Unifesp-EPM), São Paulo. 
 The study received the seal of approval from the Ethics and 
Research Committee of Unifesp, identified by the registered code 
number 1139/03. All patients gave their signed consent after agreed 
to participate in the study.
1. Subjects
Twenty-three healthy subjects and 68 patients were submitted 
to an interview for initial assessment. All patients were diagnosed 
for narcolepsy and IH using ICSD-22. The patients were divided 
into 3 groups: 43 with narcolepsy and cataplexy, 11 patients 
with narcolepsy without cataplexy and 14 patients with IH with 
long sleep duration. Others patients with others diagnoses were 
excluded: narcolepsy due to a medical condition and IH without 
long sleep duration for example. The identification of the presence 
of the HLA-DQB1*0602 allele was performed in all healthy subjects 
and patients.  
2. HLADQB1*0602 allele analysis
HLADQB1*0602 allele analysis was carried out in the 
Genetic Laboratory which collaborates with our Sleep Institute. 
The presence of DQB1*0602 was determined using the 
following procedure: The DNA was extracted from white blood 
cells. The region where the DQB1*0602 allele is located was 
amplified by a polymerase chain reaction (PCR) using primers 
of DQBF (5’- CCCGCAGAGGATTTCGTGTT - 3’) and DQBR (5’- 
AACTCCGCCCGGGTCCC - 3’). These primers amplified DQB 1 *0602 
and also the rare DQB1*0610, DQB1*0613, and DQB1*0614 
alleles as a product of 218 base pairs. 
 As an internal control for the amplifications were used in the 
same reaction of PCR, the following primers amplified the exon 3 of 
the gene DRBI: EX3f (5’-TGCCAAGTGGAGCACCCAA - 3’) and EX3r 
(5’- GCATCTTGCTCTGTGCAGAT - 3’). PCR analyses were performed 
using 35 cycles of 95ºC for 30 seconds, 35 cycles of 63ºC for 30 
seconds and 35 cycles of 72ºC for 60 seconds.  
3. Statistical analysis
Variable distribution was verified using the Kolmogorov-Smirnov 
test with values presented as averages and standard deviation. 
 The Chi-squared test was used to test the differences between 
groups of patients. The t-Student’s test for independent samples 
was used for comparison of age between the groups. Statistical 
significance was attributed when p ≤ 0.05.  
4. Results
Demographic characteristics (age and gender) were similar among 
all groups studied – Table 1.
The prevalence of the HLA-DQB1*0602 allele increased in IH and 
in narcolepsy patients with and without cataplexy when compared 
with healthy subjects (p = 0.04; p = 0.03 and p < 0.0001, 
respectively). Our data showed no difference regarding the HLA-
DQB1*0602 allele prevalence between IH and narcolepsy without 
cataplexy (p = 0.9) – Table 2. 
5. Discussion
Our understanding of narcolepsy has improved in recent 
years. The greater prevalence of the HLA-DQB1*0602 allele in 
narcoleptic patients with cataplexy is well known8,9. The discovery 
of Hypocretin-1 and its reduction through cell loss in the lateral 
hypothalamus in patients with frequent cataplexy is one possible 
explanation for the main clinical symptoms in narcolepsy9. 
Our study found that the prevalence of the HLA-DQB1*0602 allele 
was increased in the narcolepsy population, being unanimous in patients 
affected by frequent cataplexy. This finding is in accordance with those 
of a previous study3. The inherent limitation of our study could be due 
to the small number of patients and healthy subjects used. Further, it 
was impossible to study patients according to their ethnic origins.  
In our population the HLA-DQB1*0602 allele prevalence in 
patients with IH was less prevalent than that in narcolepsy patients 
with cataplexy and was similar to that in narcolepsy patients 
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without narcolepsy. The two disorders share several common 
features5,6. There is no difficulty of differential diagnosis between 
narcolepsy with cataplexy and narcolepsy without cataplexy. ICSD-2 
characterizes narcolepsy patients without cataplexy when the patient 
presents sleepiness along with two or more narcolepsy symptoms. 
IH is an exclusion diagnosis. Some psychiatric diseases, such 
as depression, can be associated with excessive sleepiness. An 
increased prevalence of some HLA allele types has been described 
in other psychiatric disorders. Depression and other psychiatric 
disorders are common in narcoleptic and IH patients10.  
Some autoimmune diseases such as Systemic Lupus Erythematosus 
and Rheumatoid Arthritis present a higher prevalence of the 
HLA-DQ*0602 and HLA DRB1 alleles, respectively11. The 
correlation of narcolepsy and rheumatoid arthritis with some 
HLA alleles could suggest a similar pathophysiology for both 
diseases. Clinical and laboratory differences suggest a possible 
pathphysiology discrepancy between the subgroups of patients 
with narcolepsy11,12.  
In clinical practice, an important step to make differential 
diagnoses is to genotype the HLA-DQB1*0602 allele in patients 
with diseases that are similar to  narcolepsy such as epilepsy, 
psychiatric disorders, sleep apnea and/or in patients who take drugs 
which affect REM sleep. Some patients taking antidepressives drugs, 
dopamine agonists, and other drugs can simulate characteristics of 
narcolepsy. Clinical and electrophysiological differentiation could be 
difficult in these situations13-15.
The gold standard exam for narcolepsy with cataplexy is Hypocretin-1 
dosage, but in patients without cataplexy and in IH, diagnosis is not 
yet automatic. HLA-DQB1*0602 allele plays a role in increasing 
information where differential diagnosis is concerned. 
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